Literature DB >> 27187622

Integrating mutation variant allele frequency into clinical practice in myeloid malignancies.

David A Sallman1, Eric Padron2.   

Abstract

Hematologic myeloid neoplasms represent a heterogeneous group of disorders with defined clinical and pathologic characteristics. However, intensive investigation into the genetic abnormalities of these diseases has not only significantly advanced our understanding, but also revolutionized our diagnostic and prognostic capabilities. Moreover, more recent discovery on the impact of clonal burden has highlighted the critical and dynamic role of clonal evolution over time, which is integrally linked to a patient's clinical trajectory. This review will highlight the evidence supporting the incorporation of allelic burden of somatic mutations into clinical practice for the diagnosis and prognosis of myeloid neoplasms.
Copyright © 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; FLT3; Myelodysplastic syndrome; Next-generation sequencing; TP53; Variant allele frequency

Mesh:

Year:  2016        PMID: 27187622     DOI: 10.1016/j.hemonc.2016.04.003

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  13 in total

1.  Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Authors:  Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

2.  Ultra-rapid somatic variant detection via real-time targeted amplicon sequencing.

Authors:  Jack Wadden; Brandon S Newell; Joshua Bugbee; Vishal John; Amy K Bruzek; Robert P Dickson; Carl Koschmann; David Blaauw; Satish Narayanasamy; Reetuparna Das
Journal:  Commun Biol       Date:  2022-07-15

3.  Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD-positive acute myeloid leukemia.

Authors:  Gabriele Lo Iudice; Eleonora De Bellis; Maria Teresa Voso; Gennaro Ciliberto; Arianna Savi; Luca Guarnera; Alice Massacci; Francesca De Nicola; Frauke Goeman; Tiziana Ottone; Mariadomenica Divona; Matteo Pallocca; Maurizio Fanciulli
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

4.  Increased number of subclones in lung squamous cell carcinoma elicits overexpression of immune related genes.

Authors:  Myung Jin Song; Sang Hoon Lee; Eun Young Kim; Yoon Soo Chang
Journal:  Transl Lung Cancer Res       Date:  2020-06

5.  Mutations in long-lived epithelial stem cells and their clonal progeny in pre-malignant lesions and in oral squamous cell carcinoma.

Authors:  Marta Melis; Tuo Zhang; Theresa Scognamiglio; Lorraine J Gudas
Journal:  Carcinogenesis       Date:  2020-11-13       Impact factor: 4.944

6.  BREAST CANCER HISTOPATHOLOGY IMAGE ANALYSIS PIPELINE FOR TUMOR PURITY ESTIMATION.

Authors:  Vahid Azimi; Young Hwan Chang; Guillaume Thibault; Jaclyn Smith; Takahiro Tsujikawa; Benjamin Kukull; Bradden Jensen; Christopher Corless; Adam Margolin; Joe W Gray
Journal:  Proc IEEE Int Symp Biomed Imaging       Date:  2017-06-19

7.  Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer.

Authors:  Kei Kunimasa; Yosuke Hirotsu; Kenji Amemiya; Yuki Nagakubo; Taichiro Goto; Yoshihiro Miyashita; Yumiko Kakizaki; Toshiharu Tsutsui; Sotaro Otake; Hiroaki Kobayashi; Rumi Higuchi; Kie Inomata; Takashi Kumagai; Hitoshi Mochizuki; Harumi Nakamura; Shin-Ichi Nakatsuka; Kazumi Nishino; Fumio Imamura; Toru Kumagai; Toshio Oyama; Masao Omata
Journal:  Cancer Med       Date:  2020-04-29       Impact factor: 4.452

8.  Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?

Authors:  Elena Fountzilas; Vassiliki Kotoula; Georgia-Angeliki Koliou; Michalis Liontos; Kyriaki Papadopoulou; Eleni Giannoulatou; Alexios Papanikolaou; Ioannis Tikas; Sofia Chrisafi; Davide Mauri; Kyriakos Chatzopoulos; Florentia Fostira; Dimitrios Pectasides; Georgios Oikonomopoulos; Dimitra Aivazi; Angeliki Andrikopoulou; Anastasios Visvikis; Gerasimos Aravantinos; Flora Zagouri; George Fountzilas
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

9.  "Direct to Drug" screening as a precision medicine tool in multiple myeloma.

Authors:  Cecilia Bonolo de Campos; Nathalie Meurice; Joachim L Petit; Alysia N Polito; Yuan Xiao Zhu; Panwen Wang; Laura A Bruins; Xuewei Wang; Ilsel D Lopez Armenta; Susie A Darvish; Greg J Ahmann; Kimberly J Henderson; Shulan Tian; Jonas J Kruse; William M Stewart; Jeremy T Larsen; Craig B Reeder; David Dingli; Prashant Kapoor; Shaji K Kumar; Rafael Fonseca; P Leif Bergsagel; Esteban Braggio; A Keith Stewart
Journal:  Blood Cancer J       Date:  2020-05-11       Impact factor: 11.037

10.  High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage.

Authors:  Martyna Borowczyk; Ewelina Szczepanek-Parulska; Szymon Dębicki; Bartłomiej Budny; Małgorzata Janicka-Jedyńska; Lidia Gil; Frederik A Verburg; Dorota Filipowicz; Elżbieta Wrotkowska; Blanka Majchrzycka; Andrzej Marszałek; Katarzyna Ziemnicka; Marek Ruchała
Journal:  Ther Adv Med Oncol       Date:  2020-03-04       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.